US Presidential Field Narrows, But Ranking The Candidates For Pharma Is Still Complicated
It is easy to see why Sen. Bernie Sanders would be the least popular pick for biopharma executives among the contenders in the Presidential race. But for industry lobbyists, it might not be the worst outcome – at least in terms of clarifying positions.
You may also be interested in...
The mid-term elections left the US Senate under Democratic leadership – but there are still big changes coming that may make life tougher on FDA and the brand name industry.
The Democratic Primary focused heavily on the idea of ‘Medicare for All,’ but the emergence of former Vice President Biden as the party standard bearer – and the overwhelming impact of the COVID-19 outbreak – suggests a very different theme for the national campaign.
The Congressionally-chartered Medicare Payment Advisory Commission is preparing a formal endorsement of a plan to overhaul Part D. It will come just in time to help move stalled legislation – and that legislation may be the best chance the drug industry has to fend off draconian pricing measures in 2021.